APUS
Apimeds Pharmaceuticals US, Inc.Company Information
- Company Name
- Apimeds Pharmaceuticals US, Inc.
- CIK
- CIK0001894525
- Category
- <br>Emerging growth company
- Ticker: Exchange
- APUS: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- APUS
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-14
- Last sale
- —
- Shares purchased (TTM)
- 536,230
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 426,282
- Shares outstanding
- 1,713,402
- Ownership
- 24.88%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -46.81%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 0 | - | - | - | -0 | 0 | 0 | ||||||
Assets Current | |||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 1 | 2 | 7 | 9 | 0 | 0 | ||||||
| Restricted Cash Current | 8 | 8 | 8 | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | - | 3 | 2 | 2 | 2 | 0 | 0 | ||||||
| Short Term Investments | - | 2 | 2 | - | - | - | - | ||||||
| Prepaid Expense Current | 2 | 3 | - | - | - | - | - | ||||||
| Other Assets Current | 0 | 0 | 0 | - | - | - | - | ||||||
| Assets Current | 11 | 13 | 14 | 9 | 10 | 0 | 0 | ||||||
| Crypto Asset Fair Value Noncurrent | 117 | 128 | 150 | - | - | - | - | ||||||
| Prepaid Expense Noncurrent | - | 0 | 0 | 0 | 0 | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | - | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Assets | 128 | 141 | 164 | 9 | 11 | 0 | 0 | ||||||
Liabilities Current | |||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | 3 | 3 | 1 | 1 | 0 | 1 | 1 | ||||||
| Warrants And Rights Outstanding | - | - | - | - | 0 | - | - | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | - | - | - | - | ||||||
| Other Notes Payable Current | 5 | 1 | - | - | - | - | - | ||||||
| Derivative Liabilities Current | 1 | 2 | 2 | - | - | - | - | ||||||
| Convertible Notes Payable Current | 9 | 8 | 7 | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | - | - | - | - | ||||||
| Liabilities Current | 21 | 15 | 11 | 1 | 1 | 2 | 1 | ||||||
Liabilities Noncurrent | |||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | - | - | - | - | ||||||
| Liabilities | 21 | 15 | 11 | 1 | 1 | 2 | 1 | ||||||
Stockholders Equity | |||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Unit Issuance Value | 4 | 8 | - | - | - | - | - | ||||||
| Additional Paid In Capital | 168 | 164 | 164 | 17 | 17 | 3 | 3 | ||||||
| Retained Earnings Accumulated Deficit | -66 | -45 | -10 | -9 | -7 | -5 | -4 | ||||||
| Stockholders Equity | 106 | 127 | 153 | 8 | 10 | -2 | -1 | ||||||
| Liabilities And Stockholders Equity | 128 | 141 | 164 | 9 | 11 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 1 | 7 | 7 | - | - | - | 0 | ||||||
| Preferred Stock Shares Outstanding | 1 | 7 | 7 | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialApimeds Pharmaceuticals US, Inc. (APUS) — SEC Financial Statements & Analysis
Apimeds Pharmaceuticals US, Inc. (APUS) is a pharmaceutical preparations company, incorporated in DE. Apimeds Pharmaceuticals US, Inc. trades on NYSE as: APUS. Apimeds Pharmaceuticals US, Inc. (APUS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Apimeds Pharmaceuticals US, Inc. carries a market cap of $15.42M, a P/E ratio of -0.27x, a P/B ratio of 0.14x, an enterprise value of $24.05M, and an EV/EBITDA multiple of -0.88x. On profitability, it posts a Return on Equity (ROE) of -100.13%, a Return on Assets (ROA) of -84.20%, and a Return on Invested Capital (ROIC) of -47.12%. Per share, it reports EPS of $-33.95, diluted EPS of $-33.95, free cash flow per share of $-7.78, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 0.51x, a quick ratio of 0.40x, working capital of $-10.39M, a debt-to-equity ratio of 0.20x, a debt ratio of 0.17, an interest coverage ratio of -6.35x, free cash flow of $-13.33M (TTM), and net debt of $8.63M. Figures sourced from SEC EDGAR.
- Market Cap
- $15.42M
- P/E TTM
- -0.27x
- EPS TTM
- $-33.95
- P/B TTM
- 0.14x
- ROE TTM
- -100.13%
- ROA TTM
- -84.20%
- Debt To Equity
- 0.20x
- Free Cash Flow TTM
- $-13.33M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Apimeds Pharmaceuticals US, Inc. in?
Apimeds Pharmaceuticals US, Inc. (APUS) operates in the Pharmaceutical Preparations industry.
What exchange does APUS trade on?
Apimeds Pharmaceuticals US, Inc. (APUS) trades on the NYSE.
Where is Apimeds Pharmaceuticals US, Inc. incorporated?
Apimeds Pharmaceuticals US, Inc. is incorporated in DE.
When was Apimeds Pharmaceuticals US, Inc. (APUS)'s most recent SEC filing?
Apimeds Pharmaceuticals US, Inc. (APUS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is APUS's market cap?
Apimeds Pharmaceuticals US, Inc. (APUS) has a market capitalization of $15.42M as of 2026-06-30.
What is APUS's EPS (earnings per share)?
Apimeds Pharmaceuticals US, Inc. (APUS)'s trailing twelve month EPS is $-33.95 as of 2026-06-30.
What is APUS's ROE (return on equity)?
Apimeds Pharmaceuticals US, Inc. (APUS)'s trailing twelve month Return on Equity (ROE) is -100.13% as of 2026-06-30.
What is APUS's ROA (return on assets)?
Apimeds Pharmaceuticals US, Inc. (APUS)'s trailing twelve month Return on Assets (ROA) is -84.20% as of 2026-06-30.
What is APUS's ROIC (return on invested capital)?
Apimeds Pharmaceuticals US, Inc. (APUS)'s trailing twelve month Return on Invested Capital (ROIC) is -47.12% as of 2026-06-30.
What is APUS's EV/EBITDA?
Apimeds Pharmaceuticals US, Inc. (APUS)'s trailing twelve month EV/EBITDA is -0.88x as of 2026-06-30.